At a press conference at SABCS 2012, Dr Peter Kaufman presents data on a A phase III multicenter study of eribulin mesylate in women with previously treated metastatic breast cancer failed to meet its co-primary endpoints of improved progression-free survival and overall survival compared with capecitabine.
Read more in ecancerNews.